Pharmacology, Cancer cell, P-glycoprotein, Doxorubicin and Biochemistry are her primary areas of study. Her work carried out in the field of Pharmacology brings together such families of science as Cell culture, ATP-binding cassette transporter, Drug delivery, Efflux and Nanoparticles for drug delivery to the brain. Her Cancer cell research includes themes of Cancer research and Immunology.
Her Cancer research research integrates issues from Gene silencing, Kinase, Programmed cell death and Cell growth. The study incorporates disciplines such as Cell, Thapsigargin and Calmodulin in addition to P-glycoprotein. Her Doxorubicin study which covers Cytotoxic T cell that intersects with HT29 Cells.
Her primary areas of study are Cancer research, Doxorubicin, Pharmacology, Biochemistry and P-glycoprotein. Her study in Cancer research is interdisciplinary in nature, drawing from both Cancer cell, Multiple drug resistance, Chronic lymphocytic leukemia and Immune system. Chiara Riganti has researched Cancer cell in several fields, including Cell, Mitochondrion, Cell biology and Cell growth.
As a part of the same scientific family, Chiara Riganti mostly works in the field of Doxorubicin, focusing on Cytotoxicity and, on occasion, Cytotoxic T cell. Chiara Riganti focuses mostly in the field of Pharmacology, narrowing it down to topics relating to In vitro and, in certain cases, In vivo and Solid lipid nanoparticle. She interconnects Efflux and Stem cell in the investigation of issues within P-glycoprotein.
The scientist’s investigation covers issues in Cancer research, Cancer cell, Doxorubicin, Cell biology and Multiple drug resistance. Her Cancer research research incorporates elements of Mitochondrion, Immune system, Cisplatin and Cytotoxicity. Her Cancer cell research is mostly focused on the topic Immunogenic cell death.
Her studies deal with areas such as Osteosarcoma, P-glycoprotein, Nanoparticle, Biophysics and Pharmacology as well as Doxorubicin. The various areas that Chiara Riganti examines in her Pharmacology study include Dialysis, Nitric oxide, Anthracycline and Peritoneal dialysis. Her Multiple drug resistance study integrates concerns from other disciplines, such as Liposome, Intracellular and ATP-binding cassette transporter.
Chiara Riganti mostly deals with Doxorubicin, Cancer research, Multiple drug resistance, P-glycoprotein and Intracellular. Chiara Riganti has included themes like Osteosarcoma, Nitric oxide, Cytotoxicity, Breast cancer and Pediatric cancer in her Doxorubicin study. Her Cancer research research also works with subjects such as
Her Multiple drug resistance research incorporates themes from Nanoparticle and Biophysics. Her work deals with themes such as Triple-negative breast cancer, Calreticulin and Pharmacology, which intersect with P-glycoprotein. Her work focuses on many connections between Intracellular and other disciplines, such as Cancer cell, that overlap with her field of interest in Signal transduction, Tumor progression, Cell biology and Mutant.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Consensus guidelines for the detection of immunogenic cell death
Oliver Kepp;Laura Senovilla;Ilio Vitale;Erika Vacchelli.
The pentose phosphate pathway: an antioxidant defense and a crossroad in tumor cell fate.
Chiara Riganti;Elena Gazzano;Manuela Polimeni;Elisabetta Aldieri.
Free Radical Biology and Medicine (2012)
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Lorenzo Galluzzi;Ilio Vitale;Sarah Warren;Sandy Adjemian.
Journal for ImmunoTherapy of Cancer (2020)
Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux.
Chiara Riganti;Erica Miraglia;Daniele Viarisio;Costanzo Costamagna.
Cancer Research (2005)
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death
Abhishek D. Garg;Lorenzo Galluzzi;Lionel Apetoh;Lionel Apetoh;Thais Baert.
Frontiers in Immunology (2015)
Zoledronic acid repolarizes tumour‐associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway
Marta Coscia;Elena Quaglino;Manuela Iezzi;Claudia Curcio.
Journal of Cellular and Molecular Medicine (2010)
Diphenyleneiodonium Inhibits the Cell Redox Metabolism and Induces Oxidative Stress
Chiara Riganti;Elena Gazzano;Manuela Polimeni;Costanzo Costamagna.
Journal of Biological Chemistry (2004)
Classical Inhibitors of NOX NAD(P)H Oxidases Are Not Specific
Elisabetta Aldieri;Chiara Riganti;Manuela Polimeni;Elena Gazzano.
Current Drug Metabolism (2008)
Artemisinin inhibits inducible nitric oxide synthase and nuclear factor NF-kB activation
Elisabetta Aldieri;Daniela Atragene;Loredana Bergandi;Chiara Riganti.
FEBS Letters (2003)
HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast
Sophie Michelle Doublier;Dimas Carolina Belisario;Manuela Polimeni;Laura Annaratone.
BMC Cancer (2012)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: